Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,575 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Pham NA, Radulovich N, Ibrahimov E, Martins-Filho SN, Li Q, Pintilie M, Weiss J, Raghavan V, Cabanero M, Denroche RE, Wilson JM, Metran-Nascente C, Borgida A, Hutchinson S, Dodd A, Begora M, Chadwick D, Serra S, Knox JJ, Gallinger S, Hedley DW, Muthuswamy L, Tsao MS. Pham NA, et al. Among authors: weiss j. Sci Rep. 2021 May 19;11(1):10619. doi: 10.1038/s41598-021-90049-1. Sci Rep. 2021. PMID: 34011980 Free PMC article.
EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.
Martins-Filho SN, Weiss J, Pham NA, Li Q, Cabanero M, Fares A, Stewart EL, Shi R, Patel D, Pal P, McConnell J, Bradbury PA, Sacher AG, Leighl NB, Grindlay A, Allison F, Li M, Yasufuku K, Shepherd FA, Moghal N, Tsao MS, Liu G. Martins-Filho SN, et al. Among authors: weiss j. Lung Cancer. 2020 Jul;145:144-151. doi: 10.1016/j.lungcan.2020.03.022. Epub 2020 May 11. Lung Cancer. 2020. PMID: 32447118
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G. Shi R, et al. Among authors: weiss j. Lung Cancer. 2020 Aug;146:78-85. doi: 10.1016/j.lungcan.2020.05.018. Epub 2020 May 21. Lung Cancer. 2020. PMID: 32521388
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
Hwang DM, Albaqer T, Santiago RC, Weiss J, Tanguay J, Cabanero M, Leung Y, Pal P, Khan Z, Lau SCM, Sacher A, Torlakovic E, Cheung C, Tsao MS. Hwang DM, et al. Among authors: weiss j. J Thorac Oncol. 2021 Sep;16(9):1490-1500. doi: 10.1016/j.jtho.2021.03.028. Epub 2021 Apr 26. J Thorac Oncol. 2021. PMID: 33915250 Free article.
Assessing therapy response in patient-derived xenografts.
Ortmann J, Rampášek L, Tai E, Mer AS, Shi R, Stewart EL, Mascaux C, Fares A, Pham NA, Beri G, Eeles C, Tkachuk D, Ho C, Sakashita S, Weiss J, Jiang X, Liu G, Cescon DW, O'Brien CA, Guo S, Tsao MS, Haibe-Kains B, Goldenberg A. Ortmann J, et al. Among authors: weiss j. Sci Transl Med. 2021 Nov 17;13(620):eabf4969. doi: 10.1126/scitranslmed.abf4969. Epub 2021 Nov 17. Sci Transl Med. 2021. PMID: 34788078
Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.
Mirhadi S, Tam S, Li Q, Moghal N, Pham NA, Tong J, Golbourn BJ, Krieger JR, Taylor P, Li M, Weiss J, Martins-Filho SN, Raghavan V, Mamatjan Y, Khan AA, Cabanero M, Sakashita S, Huo K, Agnihotri S, Ishizawa K, Waddell TK, Zadeh G, Yasufuku K, Liu G, Shepherd FA, Moran MF, Tsao MS. Mirhadi S, et al. Among authors: weiss j. Nat Commun. 2022 Apr 5;13(1):1811. doi: 10.1038/s41467-022-29444-9. Nat Commun. 2022. PMID: 35383171 Free PMC article.
5,575 results